Shashidhar H Kori

US Patent:

20110171141, Jul 14, 2011

Filed:

Jun 25, 2010

Appl. No.:

12/823981

Inventors:

Donald J. KELLERMAN - San Jose CA, US
Shashidhar H. Kori - Dublin CA, US
Scott W. Borland - Santa Clara CA, US
Thomas A. Armer - Cupertino CA, US

International Classification:

A61K 9/12
A61P 25/00

US Classification:

424 45

Abstract:

Disclosed are compositions of matter and related methods that provide a metered dose inhaler that includes a formulation having a dose that comprises a hydrofluoroalkane propellant and dihydroergotamine mesylate particles; wherein the dose includes between 0.1 mg to 4 mg of dihydroergotamine mesylate; wherein the dihydroergotamine mesylate particles have a cumulative drug substance particle size distribution with d10>0.5 micron volumetric median diameter and d90

US Patent:

20210022993, Jan 28, 2021

Filed:

Jul 21, 2020

Appl. No.:

16/934526

Inventors:

- Arlington VA, US
Shashidhar H. KORI - Clover SC, US

International Classification:

A61K 9/00
A61K 9/06
A61K 31/407

Abstract:

Disclosed are methods for a novel, counter-intuitive, non-obvious, non-invasive, simple to administer, non-systemic delivery of analgesics through the skin to the DRG and DH area to block and relieve pain in the dermatomal distribution of that particular DRG. This method of pain control provides a non-addictive, inexpensive, simple to use alternative to the present standard of care involving addictive, potentially dangerous opioid therapy.

US Patent:

20170231976, Aug 17, 2017

Filed:

May 3, 2017

Appl. No.:

15/585925

Inventors:

- Irvine CA, US
Shashidhar Kori - Mountain View CA, US
Libo Wu - Weston FL, US

International Classification:

A61K 31/48
A61K 9/00

Abstract:

8′-Hydroxy-Dihydroergotamine (8′-OH DHE) medicinal compounds, compositions, and dosage forms containing such compositions are provided. Also provided herein are methods of treatment, prevention, or amelioration of diseases, conditions or disorders selected from amyotrophic lateral sclerosis (ALS), Parkinson's disease, stress/anxiety, nausea, emesis, aggression, pain, neuropathic pain, sleeplessness, insomnia, restless leg syndrome and depression using the compounds, compositions, dosage forms and administration techniques disclosed herein.

US Patent:

20150306096, Oct 29, 2015

Filed:

Apr 29, 2015

Appl. No.:

14/699675

Inventors:

- Irvine CA, US
Shashidhar Kori - Mountain View CA, US
Libo Wu - Weston FL, US

International Classification:

A61K 31/4985

Abstract:

8′-Hydroxy-Dihydroergotamine (8′-OH DHE) medicinal compounds, compositions, and dosage forms containing such compositions are provided. Also provided herein are methods of treatment, prevention, or amelioration of diseases, conditions or disorders selected from amyotrophic lateral sclerosis (ALS), Parkinson's disease, stress/anxiety, nausea, emesis, aggression, pain, neuropathic pain, sleeplessness, insomnia, restless leg syndrome and depression using the compounds, compositions, dosage forms and administration techniques disclosed herein.

US Patent:

20150238412, Aug 27, 2015

Filed:

Apr 29, 2015

Appl. No.:

14/699797

Inventors:

- Irvine CA, US
Shashidhar H. Kori - Mountain View CA, US
Scott W. Borland - Santa Clara CA, US
Thomas A. Armer - Cupertino CA, US

International Classification:

A61K 9/00
A61K 31/48

Abstract:

Disclosed are compositions of matter and related methods that provide a metered dose inhaler that includes a formulation having a dose that comprises a hydrofluoroalkane propellant and dihydroergotamine mesylate particles; wherein the dose includes between 0.1 mg to 4 mg of dihydroergotamine mesylate; wherein the dihydroergotamine mesylate particles have a cumulative drug substance particle size distribution with d10>0.5 micron volumetric median diameter and d90

US Patent:

20150238487, Aug 27, 2015

Filed:

Apr 28, 2015

Appl. No.:

14/697906

Inventors:

- Irvine CA, US
Shashidhar Kori - Mountain View CA, US
Libo Wu - Weston FL, US

International Classification:

A61K 31/4985

Abstract:

Provided herein are 8′-Hydroxy-2-CF3-dihydroergotamine (8′OH-2-CF3-DHE) compounds, compositions, and dosage forms containing such compositions. Also provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HTand/or the 5-HTreceptor, without agonizing the 5-HTreceptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alphaand/or the alphareceptors using the compounds and compositions disclosed herein.

US Patent:

20150133456, May 14, 2015

Filed:

Jan 9, 2015

Appl. No.:

14/593792

Inventors:

- Irvine CA, US
Shashidhar Kori - Mountain View CA, US
Libo Wu - Mountain View CA, US

International Classification:

A61K 31/4985
A61M 11/02
A61M 15/00
A61M 11/00

US Classification:

514250, 544346, 12820315, 12820023

Abstract:

Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HTand/or the 5-HTreceptor, without agonizing the 5-HTreceptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alphaand/or the alphareceptors using the compounds and compositions disclosed herein.

US Patent:

20140179706, Jun 26, 2014

Filed:

Dec 19, 2013

Appl. No.:

14/134120

Inventors:

- Mountain View CA, US
Shashidhar Kori - Mountain View CA, US
Libo Wu - Mountain View CA, US

International Classification:

C07D 457/02
A61K 9/00

US Classification:

514250, 544346

Abstract:

Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HTand/or the 5-HTreceptor, without agonizing the 5-HTreceptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alphaand/or the alphareceptors using the compounds and compositions disclosed herein.